LIK 066

Drug Profile

LIK 066

Alternative Names: LIK066

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Class Antihyperglycaemics; Obesity therapies
  • Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Heart failure; Obesity; Polycystic ovary syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 27 Oct 2017 Novartis plans a phase II trial for Obesity (In adults, In the elderly) in Japan in December 2017 (NCT03320941)
  • 04 Oct 2017 Novartis initiates enrolment in a phase II trial for Obesity in USA (NCT03205150)
  • 04 Sep 2017 Novartis completes a phase II trial for Obesity (In volunteers) in USA (NCT03198767)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top